Kalbe Farma Tbk PT banner

Kalbe Farma Tbk PT
IDX:KLBF

Watchlist Manager
Kalbe Farma Tbk PT Logo
Kalbe Farma Tbk PT
IDX:KLBF
Watchlist
Price: 865 IDR -4.95% Market Closed
Market Cap: Rp40.5T

EV/S

1
Current
52%
Cheaper
vs 3-y average of 2.1

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
1
=
Enterprise Value
Rp39.9T
/
Revenue
Rp35.3T

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
1
=
Enterprise Value
Rp39.9T
/
Revenue
Rp35.3T

Valuation Scenarios

Kalbe Farma Tbk PT is trading below its 3-year average

If EV/S returns to its 3-Year Average (2.1), the stock would be worth Rp1 808.87 (109% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+141%
Average Upside
87%
Scenario EV/S Value Implied Price Upside/Downside
Current Multiple 1 Rp865
0%
3-Year Average 2.1 Rp1 808.87
+109%
5-Year Average 2.4 Rp2 083.76
+141%
Industry Average 1.5 Rp1 293.52
+50%
Country Average 1.5 Rp1 293.52
+50%

Forward EV/S
Today’s price vs future revenue

Today's Enterprise Value Revenue Forward EV/S
Rp39.9T
/
Jan 2026
Rp35.3T
=
1
Current
Rp39.9T
/
Dec 2026
Rp38.6T
=
1
Forward
Rp39.9T
/
Dec 2027
Rp41.8T
=
1
Forward
Rp39.9T
/
Dec 2028
Rp45T
=
0.9
Forward

Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
EV/S
P/E
All Countries
Close

Market Distribution

In line with most companies in Indonesia
Percentile
41st
Based on 857 companies
41st percentile
1
Low
0 — 0.6
Typical Range
0.6 — 3.3
High
3.3 —
Distribution Statistics
Indonesia
Min 0
30th Percentile 0.6
Median 1.5
70th Percentile 3.3
Max 414 768.4

Kalbe Farma Tbk PT
Glance View

Kalbe Farma Tbk PT is a renowned pharmaceutical powerhouse rooted in Indonesia, rooted in a rich history that traces back to 1966. The company has evolved from a humble startup into a multifaceted entity with a robust portfolio, making it a vital player in the health and wellness sector across Southeast Asia. The company operates across four main business divisions: prescription pharmaceuticals, consumer health products, nutritionals, and distribution & logistics. By strategically linking these divisions, Kalbe Farma masterfully balances scientific innovation with market accessibility, ensuring a wide reach and varied product offering. This diversification not only broadens its revenue streams but also mitigates risk, securing its foothold in the competitive pharmaceutical landscape. At the core of Kalbe Farma’s business model lies a commitment to research and development, which fuels its cutting-edge product innovations and enhances its competitive edge. The company dedicates substantial resources to developing new medicines and health products, constantly seeking to address emerging health concerns. Moreover, its extensive distribution network fortifies its market presence, comprising a domestic distribution arm that penetrates even the farthest reaches of the Indonesian archipelago. This network ensures that Kalbe's products are widely available, amplifying their market penetration and revenue. Additionally, Kalbe embraces partnerships and collaborations to enhance its research capabilities and expand its product offerings, fostering an ecosystem where innovation and accessibility coexist harmoniously, thereby empowering its bottom line.

KLBF Intrinsic Value
1 375.51 IDR
Undervaluation 37%
Intrinsic Value
Price Rp865
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett